Novel device-based and catheter-directed therapies for heart failure with preserved ejection fraction.
Heart failure with preserved ejection fraction (HFpEF) presents a major clinical and therapeutic challenge owing to its complex pathophysiology and pronounced clinical heterogeneity. While traditional empirical strategies targeting comorbidities offered limited success, recent advances in molecular, hemodynamic, and au...